Thank you, Todd. For those of you who may be new to our company, let me take a moment to provide some brief background information. Aemetis was founded in 2006, and we own and operate facilities with more than 110 million gallons per year of renewable fuel capacity in the U.S. and India. Included in our production portfolio is a 60 million gallon per year capacity ethanol plant located in Keyes, California, near Modesto. We also built, own, and operate a 50 million gallon per year capacity distilled biodiesel and refined glycerin bio refinery on the East Coast of Indian, near the port city of Kakinada. We will first briefly discuss our platform businesses in ethanol and biodiesel, and then review our low-cost financing initiatives and important projects in advanced biofuels. To begin, let's review our ethanol business. During the first quarter of 2017, our ethanol business grew 12% year-over-year, partially as a result of a focus on the marketing of ethanol coal products, allowing us to increase both the gallons of ethanol, and the tons of distillers' grains produced and sold. Ethanol pricing also improved by 6% year-over-year, however, are the gross margin was impacted by a 17% increase in feedstock costs due to a one-time wet winter during Q1, 2017, that caused sharply higher transportation costs from railroad delays as corn was moved from the Midwest to California. In Q2, 2017, and later this year, we expect revenues and margins to follow a positive trend due to stronger demand for gasoline from seasonal summer driving demand, stability in the enforcement of the federal renewable fuel standard, and strong demand for low-carbon biofuels in California, and in growing forward markets. Let's review our India biodiesel business. Aemetis is the leading U.S.-owned producer of biofuels in India, a country of 1.3 billion people that consumes about 25 billion gallons of petroleum diesel each year. Aemetis biodiesel produced at our India plant reduces harmful emissions by 80%, and sells as a less expensive fuel than diesel. India biodiesel and refined glycerin revenues in the first quarter of 2017 decreased on a year-over-year basis to $1.6 million from $5.3 million. The primary reason for the revenue decline is a pricing disparity between the price of diesel and the cost of feedstock in the domestic market. However, during the first and second quarters of 2017, our India business achieved important and significant milestones that expanded our customer base, including milestone one, a three-year biodiesel supply contract with a major oil company. During Q1 and Q2 2017, we negotiated and finalized the documentation of a three-year biodiesel supply contract with a major oil company that we expect to sign next week. In late 2016, Aemetis was approached for an exclusive biodiesel supply contract by one of the world's largest oil companies. Aemetis is the only India biodiesel producer approved under the low-carbon fuel standard for the delivery of tallow and used cooking oil biodiesel into California. And Aemetis filed a patent in April, 2017, for the production of low-carbon biofuels based on process technology developed by the operations and laboratory team at our India plant. These unique capabilities contributed to the opportunity for Aemetis and this major oil company to enter into a three-year supply agreement that is currently in draft from. We plan to announce the signing of the agreement with the major oil company as soon as the agreement is fully signed. And we'll be doing an investor road show and other communications to clarify any questions about this important agreement. Please note that until the agreement is signed we cannot, of course, guarantee that it will be. Milestone two is the first oil marketing company supply contract. During Q1 and Q2 2017, we won our first significant supply contract from the three India oil marketing companies that supply 70% of the fuel in India. The contract is a six-month supply agreement for 7,500 tons of biodiesel for about $6 million of revenues. And we expect to be able to win larger supply agreements in the future as we expand this business. Milestone three is a large letter of credit financing facility for shipments to the major oil company. Related to the production of biodiesel for the major oil company, we obtained a letter of credit financing facility that will support the purchase of large volumes of feedstock in order to supply more than $100 million per year of biodiesel to the major oil company. Milestone four is an expanded feedstock financing facility for domestic India sales. During Q2, 2017, we arranged a new financing facility with one of the world's largest suppliers of feedstock to purchase imported [indiscernible] and other feedstocks. This financing provides the physical supply of feedstock for existing bulk market of trucking and bus companies' customers in India. And also, for the first time, offers us the ability to offer flat pricing of biodiesel for six months or more, which is required for sales to the three national oil marketing companies. Let's now review our key financing initiatives, starting with our EB-5 update. As part of our Phase 1 EB-5 offering, we received $35 million of subordinated debt from 70 foreign investors at a 3% interest rate from escrow. After an uncertain period resulting from national political events in the U.S., the EB-5 program was extended last week without any material changes. I have presented in Asia and the Middle East during five trips in the last three quarters. And we are well positioned to make excellent progress this year on a $50 million EB-5 offering Phase 2 that is currently in process. These funds will repay the existing Third Eye capital loan, and fund expansion of company revenues and earnings. Now, let's review our two important advanced biofuels projects. In April 2016, Aemetis signed an agreement to acquire Edeniq, a biofuels technology company that converts corn kernel fiber into higher priced and lower carbon cellulosic ethanol. We are pleased with the progress [indiscernible] litigation related to enforcement of the signed definitive agreement, and we believe the documents disclosed to us in the discovery process strongly support our claims. Our LanzaTech advanced biofuels project continues to achieve important milestones. In January 2017, we received the key California Environmental Quality Act permit approval for the project, and we have executed lease for the project site. We have received Phase 1 approval from the U.S. Department of Agriculture for a loan guarantee, and have received approval for the integrated demonstration plant from the USDA that is now under construction in Washington State. Our eventual goal is to produce more than 32 million gallons per year of cellulosic ethanol, in addition to the existing 60 million gallons per year at the Keyes Plant. The initial 8 million gallons of this project is expected to generate about $50 million of revenue and more than $25 million per year of positive operating cash flow. In summary, we believe that Aemetis' is well positioned with improved fundamentals of the North American ethanol business, potential for increased biodiesel business shipping to domestic and foreign customers from our facility in India, significantly reduced interest cost by repayment of high interest debt with low interest EB-5 funding, and the positive cash flow opportunities from the LanzaTech and other advanced ethanol projects. Now, let's take a few questions from our call participants. Operator?